Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi
利妥昔单抗治疗马拉维多中心 Castleman 病的安全性、有效性和成本效益
基本信息
- 批准号:10018127
- 负责人:
- 金额:$ 14.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-16 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS related cancerAddressAdverse eventAfrica South of the SaharaAgeAwardB-LymphocytesBiological MarkersBiometryC-reactive proteinCD4 Lymphocyte CountCapitalCessation of lifeCitiesClinical Practice GuidelineClinical ResearchClinical TrialsClinical Trials DesignCommon Terminology Criteria for Adverse EventsCost Effectiveness AnalysisCountryCox Proportional Hazards ModelsDataDecision ModelingDevelopmentDiseaseDisease remissionDisease-Free SurvivalDoctor of PhilosophyDoseEnrollmentEnvironmentEtoposideFrequenciesFutureGoalsHIVHIV InfectionsHealth systemHemoglobinHerpesviridaeHerpesviridae InfectionsHigh PrevalenceHodgkin DiseaseHospitalsHuman Herpesvirus 8IncidenceIncomeInflammationInternationalK-Series Research Career ProgramsKaposi SarcomaKnowledgeLifeLymphatic DiseasesLymphoproliferative DisordersMS4A1 geneMalawiMalignant NeoplasmsMedicineMentored Research Scientist Development AwardMentorsMentorshipModelingMonoclonal AntibodiesMonoclonal Antibody CD20Morbidity - disease rateMulticentric Angiofollicular Lymphoid HyperplasiaNewly DiagnosedNon-Hodgkin&aposs LymphomaOutcomePatient-Focused OutcomesPatientsPhasePhase II Clinical TrialsPlasmaPrevalenceProspective StudiesProspective cohortProteinsPublishingRelapseReportingResearchResearch PersonnelResearch SupportResourcesRiskSafetySamplingSeroprevalencesSymptomsTimeToxic effectTrainingUnited States National Institutes of HealthWeightWorkanti-CD20antiretroviral therapyarmbaseburden of illnesscancer carecareerchemotherapycomorbiditycomparative cost effectivenesscostcost effectivecost effectivenesscost-effectiveness evaluationdisability-adjusted life yearsdisorder controlefficacy trialexperienceglobal healthhigh riskimprovedinsightinternational centerlow and middle-income countrieslow income countrymarkov modelmeetingsmicrocostingmortalitymultidisciplinaryphase 2 studypreventprimary outcomeprogramsrelapse predictionrituximabsafety testingsecondary outcomeskillswillingness to pay
项目摘要
PROJECT SUMMARY/ABSTRACT
Dr. Matthew Painschab is applying for a Fogarty International Center K01 International Research Scientist
Development Award. Dr. Painschab has shown promise as a young investigator in global health but needs
further training to achieve research independence. This award will provide him with five years of mentored
research time and he will spend >75% of the award period based at UNC Project Malawi and Kamuzu Central
Hospital in Lilongwe, the capital city of Malawi. His goal is to become an expert and independent researcher in
clinical trials and cost-effectiveness of cancer care in sub-Saharan Africa (SSA), specifically, multicentric
Castleman’s disease and other Kaposi sarcoma-associated herpesvirus (KSHV)-related diseases. His primary
mentors for this award are Dr. Satish Gopal, MD, MPH (Primary LMIC-based Mentor, cancer clinical research
in SSA) and Dr. Stephanie Wheeler, PhD, MPH (Primary US-based Mentor, decision modeling and cost-
effectiveness analysis). Through a combination of mentorship, coursework, and practical experience, Dr.
Painschab proposes to accomplish the following training objectives: 1) advanced training in clinical trials
design and implementation; 2) advanced training in microcosting and cost-effectiveness modeling; and 3)
advanced training in KSHV pathobiology. This training plan will support a rigorous research plan in MCD, a life-
threatening lymphoproliferative disorder characterized by systemic inflammation and lymphadenopathy that is
strongly associated with KSHV and human immunodeficiency virus (HIV). This disease is much more prevalent
in SSA because of a much higher prevalence of KSHV and HIV infections. Chemotherapy is rarely, if ever,
effective in preventing morbidity and mortality from this disease. However, in small studies in high income
countries, rituximab, a monoclonal antibody against CD20, a protein commonly found on B cells, has been
effective in inducing long-term remissions. In this application, we propose testing the safety and efficacy of
rituximab-based treatment for MCD (AIM 1) in a single arm, phase II study in Malawi. We will also conduct a
comprehensive microcosting study of treatment of MCD in Malawi and use outcomes from AIM 1 to establish a
Markov model (AIM 2) that we will use to analyze the cost-effectiveness of rituximab-based therapy. This
research will establish a unique prospective cohort of MCD patients and samples that can be leveraged for
future independent research awards to better understand this emerging HIV-associated comorbidity and
improve patient outcomes in both SSA and high-income countries.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew Scott Painschab其他文献
Matthew Scott Painschab的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew Scott Painschab', 18)}}的其他基金
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi
利妥昔单抗治疗马拉维多中心 Castleman 病的安全性、有效性和成本效益
- 批准号:
10189741 - 财政年份:2019
- 资助金额:
$ 14.39万 - 项目类别:
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi
利妥昔单抗治疗马拉维多中心 Castleman 病的安全性、有效性和成本效益
- 批准号:
10650780 - 财政年份:2019
- 资助金额:
$ 14.39万 - 项目类别:
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi
利妥昔单抗治疗马拉维多中心 Castleman 病的安全性、有效性和成本效益
- 批准号:
10461722 - 财政年份:2019
- 资助金额:
$ 14.39万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 14.39万 - 项目类别:
Research Grant